Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongluo Mingmu is a Traditional Chinese Medicine (TCM) formulation, typically administered as oral granules or capsules, specifically developed for the treatment of retinal vascular disorders such as non-proliferative diabetic retinopathy (NPDR). The formulation is designed according to TCM principles to "unblock collaterals" (Tongluo) and "improve eyesight" (Mingmu), primarily by enhancing retinal microcirculation, reducing vascular permeability, and providing neuroprotective effects to the retina. In clinical practice and research, such as trials sponsored by the First Hospital of Northwest University, it is frequently evaluated as an adjunctive therapy alongside Western vasoprotective agents like calcium dobesilate to optimize fundus recovery and visual acuity in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongluo Mingmu.